 |
|
Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study
Young Eun Chon, Dong Yun Kim, Mi Na Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Yeonjung Ha, Joo Ho Lee, Kwan Sik Lee, Beodeul Kang, Jung Sun Kim, Hong Jae Chon, Do Young Kim
Clin Mol Hepatol. 2024;30(3):345-359. Published online 2024 Mar 12 DOI: https://doi.org/10.3350/cmh.2023.0553
|
|
Citations to this article as recorded by
 EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Bruno Sangro, Josepmaria Argemi, Maxime Ronot, Valerie Paradis, Tim Meyer, Vincenzo Mazzaferro, Peter Jepsen, Rita Golfieri, Peter Galle, Laura Dawson, Maria Reig
Journal of Hepatology.2025; 82(2): 315. CrossRef Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan
Jaekyung Cheon, Shigeo Shimose, Hyung-Don Kim, Takashi Niizeki, Min-Hee Ryu, Tomotake Shirono, Baek-Yeol Ryoo, Hideki Iwamoto, Changhoon Yoo
Journal of Cancer Research and Clinical Oncology.2025;[Epub] CrossRef Treatment for hepatocellular carcinoma after immunotherapy
Landon L. Chan, Tsz Tung Kwong, Johnny C.W. Yau, Stephen L. Chan
Annals of Hepatology.2025; 30(2): 101781. CrossRef Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter Study
Christian Möhring, Moritz Berger, Farsaneh Sadeghlar, Xin Zhou, Taotao Zhou, Malte Benedikt Monin, Kateryna Shmanko, Sabrina Welland, Friedrich Sinner, Birgit Schwacha-Eipper, Ulrike Bauer, Christoph Roderburg, Angelo Pirozzi, Najib Ben Khaled, Peter Schr
Cancers.2025; 17(6): 972. CrossRef Therapeutic Sequences of Systemic Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma: Real‐World Analysis of the IMMUreal Cohort
Najib Ben Khaled, Valentina Zarka, Bernard Hobeika, Julia Schneider, Monika Rau, Alexander Weich, Hans Benno Leicht, Liangtao Ye, Ignazio Piseddu, Michael T. Dill, Arne Kandulski, Matthias Pinter, Ursula Ehmer, Peter Schirmacher, Jens U. Marquardt, Julia
Alimentary Pharmacology & Therapeutics.2025; 61(11): 1755. CrossRef Application of the associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) technique in conversion therapy for hepatocellular carcinoma
Jingyun Ning, Cao Dai, Qin Liu, Haoming Lin, Rui Zhang
British Journal of Surgery.2025;[Epub] CrossRef Recent advances in polydopamine-coated metal–organic frameworks for cancer therapy
Jingchao He, Guangtian Wang, Yongfang Zhou, Bin Li, Pan Shang
Frontiers in Bioengineering and Biotechnology.2025;[Epub] CrossRef The potential of lenvatinib in breast cancer therapy
Yuefeng Shang, Tong Liu, Wenjing Wang
Medical Oncology.2024;[Epub] CrossRef Sorafenib and SIAIS361034, a novel PROTAC degrader of BCL-xL, display synergistic antitumor effects on hepatocellular carcinoma with minimal hepatotoxicity
Xiaoyi Zhang, Yachuan Tao, Zhongli Xu, Biao Jiang, Xiaobao Yang, Taomin Huang, Wenfu Tan
Biochemical Pharmacology.2024; 230: 116542. CrossRef Second-line systemic therapy after atezolizumab plus bevacizumab: Is it time to boldly go beyond the known?
Edoardo G. Giannini
Digestive and Liver Disease.2024; 56(12): 2077. CrossRef Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”
Young Eun Chon, Dong Yun Kim, Hong Jae Chon, Do Young Kim
Clinical and Molecular Hepatology.2024; 30(4): 1005. CrossRef Improved survival with second-line hepatic arterial infusion chemotherapy after atezolizumab-bevacizumab failure in hepatocellular carcinoma
Ji Yeon Lee, Jaejun Lee, Suho Kim, Jae-sung Yoo, Ji Hoon Kim, Keungmo Yang, Ji Won Han, Jeong Won Jang, Jong Yong Choi, Seung Kew Yoon, Ho Jong Chun, Jung Suk Oh, Pil Soo Sung
Frontiers in Oncology.2024;[Epub] CrossRef
|